Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Stocks
Currencies
Cryptocurrencies
Metals
Indices
Commodities
ETFs
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
News
Top Providers News
Top Providers News
Symbols
Market
Provider
Time
Symbols
News
Provider
2026.10.27
Asbury Automotive Gr Q3 Adj. EPS $6.16 Misses $6.42 Estimate, Sales $4.413B Miss $4.510B Estimate
Benzinga
2026.10.27
IQVIA Holdings Raises FY2026 Adj EPS Guidance from $12.80-$13.00 to $12.90-$13.00 vs $12.96 Est; Raises FY2026 Sales Guidance from $17.275B-$17.475B to $17.350B-$17.500B vs $17.419B Est
Benzinga
2026.10.27
Repligen Raises FY2026 Adj EPS Guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 Est; Raises FY2026 Sales Guidance from $813.000M-$835.000M to $844.000M-$852.000M vs $829.693M Est
Benzinga
2026.10.27
SoFi Techs Q3 Adj. EPS $0.18 Beats $0.17 Estimate, Sales $1.371B Beat $1.256B Estimate
Benzinga
2026.10.27
American Tower Q3 FFO $2.87 Beats $2.68 Estimate, Sales $2.785B Beat $2.761B Estimate
Benzinga
2026.10.27
Yemen's Houthi Rebels Claim They Launched Attack On Saudi Arabia's Ras Tanura Refinery
Benzinga
2026.10.27
Xylem To Divest Its Water International And Specialty Flow Control Units; Will Move To Three-Segment Structure From January 1, 2027
Benzinga
2026.10.27
Why Is Broadcom Stock Gaining Tuesday?
Benzinga
2026.10.27
Coca-Cola Raises FY2026 Adj EPS Guidance from $3.27-$3.30 to $3.33 vs $3.31 Est
Benzinga
2026.10.27
Xylem Sees Q4 Adj EPS $1.39-$1.44 vs $1.63 Est; Sees Sales $2.300B vs $2.446B Est
Benzinga
2026.10.27
Johnson Controls Intl Sees FY2027 Adj EPS $6.15-$6.30 vs $6.16 Est
Benzinga
2026.10.27
Johnson Controls Intl Sees Q1 Adj EPS $1.15-$1.20 vs $1.12 Est
Benzinga
2026.10.27
Invesco Q3 Adj. EPS $0.72 Misses $0.74 Estimate, Sales $1.382B Miss $1.386B Estimate
Benzinga
2026.10.27
Johnson Controls Intl Q4 Adj. EPS $1.66 Beats $1.58 Estimate, Sales $7.113B Beat $7.029B Estimate
Benzinga
2026.10.27
Xylem Q3 Adj. EPS $1.44 Misses $1.45 Estimate, Sales $2.201B Miss $2.276B Estimate
Benzinga
2026.10.27
Xylem Lowers FY2026 Adj EPS Guidance from $5.55-$5.70 to $5.40-$5.45 vs $5.66 Est; Lowers FY2026 Sales Guidance from $9.200B to $8.950B vs $9.191B Est
Benzinga
2026.10.27
Coca-Cola Q3 Adj. EPS $0.91 Beats $0.88 Estimate, Sales $13.400B Beat $12.920B Estimate
Benzinga
2026.10.27
SNDL Q3 EPS $(0.21) Misses $(0.01) Estimate, Sales $237.994M Beat $233.777M Estimate
Benzinga
2026.10.27
Pentair Lowers FY2026 GAAP EPS Guidance from $3.86-$4.06 to $3.76 vs $3.90 Est
Benzinga
2026.10.27
Pentair Sees Q4 GAAP EPS $1.07 vs $1.10 Est
Benzinga
2026.10.27
Pentair Sees Q4 Adj EPS $1.15 vs $1.22 Est; Sees Sales $1.092B-$1.113B vs $1.019B Est
Benzinga
2026.10.27
Oppenheimer Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $10
Benzinga
2026.10.27
Pentair Narrows FY2026 Adj EPS Guidance from $4.60-$4.80 to $4.70 vs $4.65 Est; Raises FY2026 Sales Guidance from $3.884B-$4.009B to $4.051B vs $3.949B Est
Benzinga
2026.10.27
Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible
Benzinga
2026.10.27
Wolfe Research Downgrades M&T Bank to Underperform
Benzinga
2026.10.27
Pfizer Announces That Topline Results In The Phase 3 MagnetisMM-32 Trial Of ELREXFIO Demonstrated Clinically Meaningful And Statistically Significant Benefit For Patients Whose Disease Progressed After Anti-CD38 Therapy And Lenalidomide, With Median PFS...
Benzinga
2026.10.27
Oppenheimer Initiates Coverage On MSC Income Fund with Outperform Rating, Announces Price Target of $15
Benzinga
2026.10.27
Aclaris Therapeutics Prices $50M Offering Of 7,785,714 Shares And Warrants To Purchase 6.5M Shares At $3.50/Unit
Benzinga
2026.10.27
Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113
Benzinga
2026.10.27
Community Financial Q3 Adj. EPS $1.27 Beats $1.19 Estimate, Sales $227.291M Beat $224.672M Estimate
Benzinga
1
...
492
493
494
495
496
497
...
709
>